New cancer drug ESG401 shows promise in early trial
NCT ID NCT04892342
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 45 times
Summary
This study tested a new drug called ESG401 in 156 people with advanced solid tumors (like breast, lung, or colon cancer) that had stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see if it could shrink tumors. The trial had two phases: first to test safety, then to test effectiveness at the chosen dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, COLORECTAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ESG401 (a drug given by IV infusion)
What this could lead to
If successful, ESG401 could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase I/II) with a small number of participants. The drug may not shrink tumors or could cause significant side effects. Results may not apply to all cancer types studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.